IgGの糖鎖異常と慢性炎症（関連論文）

• A novel pathogenesis of inflammatory bowel disease from the perspective of glyco-immunology. Shinzaki S, Iijima H, Fujii H, Kamada Y, Naka T, Takehara T, Miyoshi E. J Biochem. 2017 May 1;161(5):409-415.
• Role of aberrant IgG glycosylation in the pathogenesis of inflammatory bowel disease. Miyoshi E, Shinzaki S, Fujii H, Iijima H, Kamada Y, Takehara T. Proteomics Clin Appl. 2016 Apr;10(4):384-90.
• Twin studies on the effect of genetic factors on serum agalactosyl immunoglobulin G levels. Azuma K, Shinzaki S, Asazawa H, Kuroki E, Kawamoto S, Kamada Y, Hayakawa K, Miyoshi E. Biomed Rep. 2014 Mar;2(2):213-216.
• Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease. Shinzaki S, Kuroki E, Iijima H, Tatsunaka N, Ishii M, Fujii H, Kamada Y, Kobayashi T, Shibukawa N, Inoue T, Tsujii M, Takeishi S, Mizushima T, Ogata A, Naka T, Plevy SE, Takehara T, Miyoshi E. Inflamm Bowel Dis. 2013 Feb;19(2):321-31.
• Altered oligosaccharide structures reduce colitis induction in mice defective in β-1,4-galactosyltransferase. Shinzaki S, Iijima H, Fujii H, Kuroki E, Tatsunaka N, Inoue T, Nakajima S, Egawa S, Kanto T, Tsujii M, Morii E, Takeishi S, Asano M, Takehara T, Hayashi N, Miyoshi E. Gastroenterology. 2012 May;142(5):1172-82.
• IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Shinzaki S, Iijima H, Nakagawa T, Egawa S, Nakajima S, Ishii S, Irie T, Kakiuchi Y, Nishida T, Yasumaru M, Kanto T, Tsujii M, Tsuji S, Mizushima T, Yoshihara H, Kondo A, Miyoshi E, Hayashi N. Am J Gastroenterol. 2008 May;103(5):1173-81.

フコシル化ハプトグロビン

• Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells. Ohkawa Y, Kitano M, Maeda K, Nakano M, Kanto N, Kizuka Y, Seike M, Azuma A, Yamaguchi Y, Ookawara T, Miyoshi E, Taniguchi N. Antioxid Redox Signal. 2023 Mar 6. doi:10.1089/ars.2022.0010.
• Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer. Hatano K, Yoneyama T, Hatakeyama S, Tomiyama E, Tsuchiya M, Nishimoto M, Yoshimura K, Miyoshi E, Uemura H, Ohyama C, Nonomura N, Fujita K. Br J Cancer. doi: 10.1038/s41416-021-01637-x.
• Transcription factor SP1 regulates haptoglobin fucosylation via induction of GDP-fucose transporter 1 in the hepatoma cell line HepG2. Kondo J, Sakata N*, Morishita K, Hayashibara A, Sakon D, Takamatsu S, Asakura N, Suzuki T, Miyoshi E. Biochem Biophys Rep. 2022 Oct 25;32:101372. doi: 10.1016/j.bbrep.2022.101372. eCollection 2022 Dec. *co-first author
• Identification of fucosylated haptoglobin-producing cells in pancreatic cancer tissue and its molecular mechanism. Ito N, Yamada M, Morishita K, Nojima S, Motooka K, Sakata N, Asuka T, Otsu R, Takamatsu S, Kamada Y, Mori S, Akita H, Eguchi H, Morii E, Miyoshi E. Glycoconj J. 2021 Feb 1. doi: 10.1007/s10719-020-09970-8.
• Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis. Motooka K, Morishita K, Ito N, Shinzaki S, Tashiro T, Nojima S, Shimizu K, Date M, Sakata N, Yamada M, Takamatsu S, Kamada Y, Iijima H, Mizushima T, Morii E, Takehara T, Miyoshi E. World J Gastroenterol. 2021 Jan 14;27(2):162-175.
• Identification of the epitope of 10-7G glycan antibody to recognize cancer-associated haptoglobin.Morishita K, Maki Y, Takamatsu S, Ito N, Koda S, Motooka K, Kamada Y, Kajihara Y, Miyoshi E. Anal Biochem. 2020 Mar 15;593:113588.
• Functional glycomics: Application to medical science and hepatology.Miyoshi E, Kamada Y, Suzuki T. Hepatol Res. 2020 Feb;50(2):153-164.
• Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis. Morishita K, Ito N, Koda S, Maeda M, Nakayama K, Yoshida K, Takamatsu S, Yamada M, Eguchi H, Kamada Y, Miyoshi E. Clin Chim Acta. 2018 Dec;487:84-89.
• Establishment of an antibody specific for cancer-associated haptoglobin: a possible implication of clinical investigation. Nishino K, Koda S, Kataoka N, Takamatsu S, Nakano M, Ikeda S, Kamamatsu Y, Morishita K, Moriwaki K, Eguchi H, Yamamoto E, Kikkawa F, Tomita Y, Kamada Y, Miyoshi E. Oncotarget. 2018 Jan 29;9(16):12732-12744.
• Reevaluation of Pholiota squarrosa lectin-reactive haptoglobin as a pancreatic cancer biomarker using an improved ELISA system. Kusama K, Okamoto Y, Saito K, Kasahara T, Murata T, Ueno Y, Kobayashi Y, Kamada Y, Miyoshi E. Glycoconj J. 2017 Aug;34(4):537-544.
• Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C. Tawara S, Tatsumi T, Iio S, Kobayashi I, Shigekawa M, Hikita H, Sakamori R, Hiramatsu N, Miyoshi E, Takehara T. PLoS One. 2016 Mar 22;11(3):e0151828.
• Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis. Ueda M, Kamada Y, Takamatsu S, Shimomura M, Maekawa T, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kobayashi Y, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E. Pancreatology. 2016 Mar-Apr;16(2):238-43.
• A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E. Hepatology. 2015 Nov;62(5):1433-43.
• Establishment of a novel lectin-antibody ELISA system to determine core-fucosylated haptoglobin. Shimomura M, Nakayama K, Azuma K, Terao N, Nishino K, Takamatsu S, Nakano M, Takahashi S, Kobayashi Y, Murata K, Kamada Y, Miyoshi E. Clin Chim Acta. 2015 Jun 15;446:30-6.
• Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Asazawa H, Kamada Y, Takeda Y, Takamatsu S, Shinzaki S, Kim Y, Nezu R, Kuzushita N, Mita E, Kato M, Miyoshi E.. Clin Chem Lab Med. 2015 Jan;53(1):95-102.
• Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. Kamada Y, Akita M, Takeda Y, Yamada S, Fujii H, Sawai Y, Doi Y, Asazawa H, Nakayama K, Mizutani K, Fujii H, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. PLoS One. 2013 Jun 21;8(6):e66328.
• Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, Kamihagi K, Koyama N, Yamada S, Daigo Y, Nakamura Y, Taniguchi N, Miyoshi E. Clin Chim Acta. 2013 Feb 18;417:48-53.
• Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Takeda Y, Shinzaki S, Okudo K, Moriwaki K, Murata K, Miyoshi E. Cancer. 2012 Jun 15;118(12):3036-43.
• Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Matsumoto H, Shinzaki S, Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Kanke F, Satomura S, Kumada T, Miyoshi E. Clin Chem Lab Med. 2010 Apr;48(4):505-12.
• Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Nakagawa T, Matsumoto H, Asahi M, Koyama N, Miyoshi E. Biochem Biophys Res Commun. 2008 Dec 19;377(3):792-6.
• Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, Tajiri M, Wada Y, Taniguchi N, Miyoshi E. Int J Cancer. 2008 May 15;122(10):2301-9.
• Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, Gu J, Kondo A, Taniguchi N, Miyoshi E. J Biol Chem. 2006 Oct 6;281(40):29797-806.
• Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, Moriwaki K, Murata K, Ohigashi H, Yokoyama S, Eguchi H, Ishikawa O, Ito T, Kato M, Kasahara A, Kawano S, Gu J, Taniguchi N, Miyoshi E. Int J Cancer. 2006 Jun 1;118(11):2803-8.

Mac-2 binding protein

• Twin research shows glycan changes are more susceptible to environmental factors than their carrier glycoproteins. Asuka T, Kamada Y, Morishita K, Fukuoka T, Takamatsu S, Kondo J, Watanabe M, Sakai N, Hayakawa K, Miyoshi E.; Osaka Twin Research Group.Oncogene. 2022 Aug 15. doi: 10.1038/s41388-022-02434-3. Online ahead of print.
• Establishment of a novel 70K Mac-2 binding protein antibody through screening of fucosylation-related antibodies. Masuda M, Asuka T, Terao N, Nishino S, Ikeda S, Takamatsu S, Kondo J,Miyoshi E. Glycoconj J. 2023 Feb 14. doi: 10.1007/s10719-023-10099-7. Online ahead of print.
• Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with nonalcoholic fatty liver disease. Kamada Y, Nakahara T, Munekage K, Fujii H, Sawai Y, Doi Y, Ono M, Hyogo H, Sumida Y, Morishita K, Asuka T, Ouchida T, Imai Y, and Miyoshi E; Japan Study Group of NAFLD (JSG-NAFLD). Hepatol Commun in press
• Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study. Study.Kamada Y, Morishita K, Koseki M, Nishida M, Asuka T, Naito Y, Yamada M, Takamatsu S, Sakata Y, Takehara T, Miyoshi E. Nutrients. 2020 Jun 12;12(6):1770. doi: 10.3390/nu12061770
• Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E.; Japan Study Group of NAFLD (JSG-NAFLD), Hepatol Commun. 2017 Aug 16;1(8):780-791.
• Mac-2 Binding Protein is a Useful Liver Fibrosis Biomarker for NAFLD/NASH. Kamada Y and Miyoshi E. TIGG (Trends in Glycoscience and Glycotechnology). 2017 29; E85-E92.
• Establishment of mouse Mac-2 binding protein enzyme-linked immunosorbent assay and its application for mouse chronic liver disease models. Iwata A, Kamada Y, Ebisutani Y, Yamamoto A, Ueda Y, Arai H, Fujii H, Takamatsu S, Maruyama N, Maeda M, Takehara T, Miyoshi E. Hepatol Res. 2017 Aug;47(9):902-909.
• Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis. Maekawa T, Kamada Y, Ebisutani Y, Ueda M, Hata T, Kawamoto K, Takamatsu S, Mizutani K, Shimomura M, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E.
• Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C. Tawara S, Tatsumi T, Iio S, Kobayashi I, Shigekawa M, Hikita H, Sakamori R, Hiramatsu N, Miyoshi E, Takehara T. PLoS One. 2016 Mar 22;11(3):e0151828.
• A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E. Hepatology. 2015 Nov;62(5):1433-43.
• Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Kamada Y, Fujii H, Fujii H, Sawai Y, Doi Y, Uozumi N, Mizutani K, Akita M, Sato M, Kida S, Kinoshita N, Matuyama N, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. Proteomics Clin Appl. 2013 Oct;7(9-10):648-56.

Fetuin-Aと肝疾患

• Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Kamada Y, Sato M, Takeda Y, Kida S, Ohara Y, Fujii H, Akita M, Mizutani K, Yoshida Y, Yamada M, Hougaku H, Takehara T, Miyoshi E.Liver Int. 2015 Mar;35(3):925-35. doi: 10.1111/liv.12478. Epub 2014 Feb 26.
• Value of fetuin-A as a predictor of liver fibrosis in patients with nonalcoholic fatty liver disease. Author's reply. Kamada Y, Miyoshi E. Liver Int. 2015 Aug;35(8):2062. doi: 10.1111/liv.12833. Epub 2015 Apr 7
• Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma. Betesh L, Comunale MA, Wang M, Liang H, Hafner J, Karabudak A, Giama NH, Moser CD, Miyoshi E, Roberts LR, Block TM, Mehta A. Proteomics Clin Appl. 2017 Sep;11(9-10). doi: 10.1002/prca.201600141.
• Identification of sialylated glycoproteins in Doxorubicin-treated hepatoma cells with glycoproteomic analyses. Azuma K, Serada S, Takamatsu S, Terao N, Takeishi S, Kamada Y, Naka T, Miyoshi E. J Proteome Res. 2014 Nov 7;13(11):4869-77. doi: 10.1021/pr5004399. Epub 2014 Sep 5.
• Identification of various types of α2-HS glycoprotein in sera of patients with pancreatic cancer: Possible implication in resistance to protease treatment. Kuwamoto K, Takeda Y, Shirai A, Nakagawa T, Takeishi S, Ihara S, Miyamoto Y, Shinzaki S, Ko JH, Miyoshi E. Mol Med Rep. 2010 Jul-Aug;3(4):651-6. doi: 10.3892/mmr_00000311.
• A specific detection of GlcNAcbeta1-6Manalpha1 branches in N-linked glycoproteins based on the specificity of N-acetylglucosaminyltransferase VI. Watanabe T, Ihara H, Miyoshi E, Honke K, Taniguchi N, Taguchi T. Glycobiology. 2006 May;16(5):431-9. Epub 2006 Jan 20.

慢性膵炎のバイオマーカー

• Enterococcus spp. have higher fitness for survival, in a pH-dependent manner, in pancreatic juice among duodenal bacterial flora. Itoyama S, Noda E, Takamatsu S, Kondo J, Kawaguchi R, Shimosaka M, Fukuoka T, Motooka D, Nakamura S, Tanemura M, Mitsufuji S, Iwagami Y, Akita H, Tobe T, Kamada Y, Eguchi H, Miyoshi E. JGH Open. 2022 Jan 5;6(1):85-90. doi: 10.1002/jgh3.12703.
• Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Maekawa T, Fukaya R, Takamatsu S, Itoyama S, Fukuoka T, Yamada M, Hata T, Nagaoka S, Kawamoto K, Eguchi H, Murata K, Kumada T, Ito T, Tanemura M, Fujimoto K, Tomita Y, Tobe T, Kamada Y, Miyoshi E. Biochem Biophys Res Commun. 2018 Dec 2;506(4):962-969.
• Application of glycoscience to the early detection of pancreatic cancer. Miyoshi E, Kamada Y. Cancer Sci. 2016 Oct;107(10):1357-1362
• Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis. Maekawa T, Kamada Y, Ebisutani Y, Ueda M, Hata T, Kawamoto K, Takamatsu S, Mizutani K, Shimomura M, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E. World J Gastroenterol. 2016 May 7;22(17):4403-10.
• Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis. Ueda M, Kamada Y, Takamatsu S, Shimomura M, Maekawa T, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kobayashi Y, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E. Pancreatology. 2016 Mar-Apr;16(2):238-43.
• Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Furukawa K, Kawamoto K, Eguchi H, Tanemura M, Tanida T, Tomimaru Y, Akita H, Hama N, Wada H, Kobayashi S, Nonaka Y, Takamatsu S, Shinzaki S, Kumada T, Satomura S, Ito T, Serada S, Naka T, Mori M, Doki Y, Miyoshi E, Nagano H. Pancreas. 2015 Jan;44(1):93-8.
• Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Tomita Y, Azuma K, Nonaka Y, Kamada Y, Tomoeda M, Kishida M, Tanemura M, Miyoshi E. Pancreas. 2014 Oct;43(7):1032-41.
• Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Miyoshi E, Nakano M. Proteomics. 2008 Aug;8(16):3257-62.
• Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, Tajiri M, Wada Y, Taniguchi N, Miyoshi E. Int J Cancer. 2008 May 15;122(10):2301-9.

オルガノイド培養を用いた がん治療効果予測バイオマーカー開発

• Liver ductal organoids reconstruct intrahepatic biliary trees in decellularized liver grafts Tomofuji K, Fukumitsu K, Kondo J, Horie H, Makino K, Wakama S, Ito T, Oshima Y, Ogiso S, Ishii T, Inoue M, Hatano E. Biomaterials. 2022 Jun 1;287:121614. doi: 10.1016/j.biomaterials.2022.121614.
• Distinct but interchangeable subpopulations of colorectal cancer cells with different growth fates and drug sensitivity. Coppo R, Kondo J, Iida K, Okada M, Onuma K, Tanaka Y, Kamada M, Ohue M, Kawada K, Obama K, Inoue M. iScience. 2023 Jan 13;26(2):105962. doi: 10.1016/j.isci.2023.105962. eCollection 2023 Feb 17.
• Hepatocyte differentiation from mouse liver ductal organoids by transducing 4 liver-specific transcription factors. Tomofuji K, Kondo J, Onuma K, Coppo R, Horie H, Oyama K, Miyoshi E, Fukumitsu K, Ishii T, Hatano E, Inoue M. Hepatol Commun. 2023 Apr 14;7(5):e0134. doi: 10.1097/HC9.0000000000000134. eCollection 2023 May 1.
• Heterogenous chemosensitivity of a panel of organoid lines derived from small cell neuroendocrine carcinoma of the uterine cervix Tanaka M, Kondo J, Kaneko K, Endo H, Onuma K, Coppo R, Masuda M, Kamiura S, Yoshino K, Ueda Y, Kakeya H, Kimura T, Inoue M Hum Cell. 2021 May;34(3):889-900.
• Study of glycosylation of prostate-specific antigen secreted by cancer tissue-originated spheroids reveals new candidates for prostate cancer detection Ideo H, Kondo J, Nomura T, Nonomura N, Inoue M, Amano J 　Sci Rep. 2020 Feb 17;10, Article number: 2708
• Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoidsBanda M, McKim K, Myers M, Inoue M, Parsons B Plos One 2020 Sep 8; 15(9): e0238862.
• Application of Cancer Organoid Model for Drug Screening and Personalized Therapy.(Review) Kondo J, Inoue M Cells 2019, 8(5), 470; https://doi.org/10.3390/cells8050470
• High-throughput screening in colorectal cancer tissue-originated spheroids. Kondo J, Ekawa T, Endo H, Yamazaki K, Tanaka N, Kukita Y, Okuyama H, Okami J, Imamura F, Ohue M, Kato K, Nomura T, Kohara A, Mori S, Dan S, Inoue M. Cancer Sci. 2019 Jan;110(1):345-355. doi: 10.1111/cas.13843.
• p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Hsieh MH, Choe JH, Gadhvi J, Kim YJ, Arguez MA, Palmer M, Gerold H, Nowak C, Do H, Mazambani S, Knighton JK, Cha M, Goodwin J, Kang MK, Jeong JY, Lee SY, Faubert B, Xuan Z, Abel ED, Scafoglio C, Shackelford DB, Minna JD, Singh PK, Shulaev V, Bleris L, Hoyt K, Kim J, Inoue M, DeBerardinis RJ, Kim TH, Kim JW.  Cell Rep. 2019 Aug 13;28(7):1860-1878.e9. doi: 10.1016/j.celrep.2019.07.027.
• Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC. Nat Med. 2018 Feb;24(2):194-202.
• p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia. Short SP*, Kondo J*, Smalley-Freed WG, Takeda H, Dohn MR, Powell AE, Carnahan RH, Washington MK, Tripathi M, Payne DM, Jenkins NA, Copeland NG, Coffey RJ, Reynolds AB. (* co-first authors) J Clin Invest. 2017 Dec 1;127(12):4462-4476.
• Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Kondo J, Endo H, Okuyama H, Ishikawa O, Iishi H, Tsujii M, Ohue M, Inoue M. Proc Natl Acad Sci U S A. 2011;108(15):6235-40.